Reported about 2 months ago
Trinity Biotech plc's stock surged over 54% as the company reported a significant rise in orders for its TrinScreen HIV product. With session trading of 14.32 million shares, a marked increase in production capacity aligns with an expected sales revenue adjustment for 2024, now projected at $10 million, up from $8 million. CEO John Gillard highlighted manufacturing capacity increases in response to a global health emergency and expressed optimism for enhanced gross margins as operational efficiency improves.
Source: YAHOO